Teves, Justine Lloyd P.
HRN: 02-85-62 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/30/2024
CO-AMOXICLAV 625MG (TAB)
08/30/2024
09/06/2024
PO
625mg
TID
Lacerated Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes